

## R-spondin3 is associated with basal-progenitor behavior in normal and tumor mammary cells

### Supplementary Tables

**Supplementary Table S1.** Samples of malignant and benign breast lesions used for RSPO3 expression analysis by IHC

Diagnosis	RSPO3			
	Neoplasia	Non- neoplastic breast tissue		
		Lobular structure	Ductal structure	Stroma
DCInNOS	Negative	Absent	Luminal columnar cells ++/+++	Negative
DCInNOS	+++	Mioepithelial and basal columnar cells +++	Basal cell +++	Lymphocytes +++
DCInNOS	+	Absent	Absent	lymphocytes +
DCInNOS	++/+++	Absent	Absent	Negative
DCInNOS	Negative	Absent	Luminal and basal columnar cells +++	Negative
DCInNOS	Negative	Absent	Absent	Negative
DCInNOS	+++	Mioepithelial cells +++	Luminal and Basal columnar cells +++	Fibroblast +++ Lymphocytes +++
DCIS + DCInNOS	++	Absent	Absent	Absent
DCInNOS	+	Absent	Absent	Negative
DCInNOS	Negative	Absent	Basal columnar cells +++	Negative
DCInNOS	++	Absent	Absent	Negative
DCInNOS	++	Absent	Luminal and basal columnar cells +++	Negative
DCInNOS	+/++	Absent	Luminal and basal columnar cells +++	Negative
DCInNOS	+++	Absent	Absent	Negative
DCInf. mucinous	+	Mioepithelial and basal columnar cells +++	Luminal and basal columnar cells +++	Lymphocytes +++
LCIS +LCInf.	++	Hyperplasia Mioepithelial cells +++	Basal columnar cells +++	Negative
LCIS + Inf.	++/+++	Mioepithelial cells ++	Luminal and basal columnar cells ++	Negative
LCInf.	Negative	Absent	Luminal and basal columnar cells ++	Negative
Dysplasia fibrous	Absent	Mioepithelial and basal columnar cells +++	Luminal and basal columnar cells +++	Lymphocytes +++
Dysplasia fibrous	Absent	Mioepithelial ++ and basal columnar cells +++	Absent	Negative
Dysplasia fibrous-cystic	Absent	Hyperplasia Mioepithelial cells +++	Basal columnar cells +++ Mioepithelial cells +++	Negative

**DCIS: ductal carcinoma *in situ*; DCInf. NOS: ductal carcinoma infiltrative not otherwise specified; LCIS: lobular carcinoma *in situ*; LCInf.: lobular carcinoma infiltrative. Positive: (+) mild, (++) moderate and (+++) intense.**

**Supplementary Table S2.** Comparative analysis of RSPO3 expression and cancer stages by IHC using a breast cancer tissue micro-array

Cancer stage	RSPO3					
	Negative		Positive		Total	
	n	%	n	%	n	%
<b>“Early”(0-III A)</b>	20	31.2	44	68.8	<b>64</b>	<b>100</b>
<b>IIIB- IV</b>	2	20.0	8	80.0	<b>10</b>	<b>100</b>
<b>Total</b>	<b>22</b>	<b>29.7</b>	<b>52</b>	<b>41.9</b>	<b>74</b>	<b>100</b>

Stage is expressed as a number on a scale of 0 through IV. Fisher test, p value=0,713. Non-statistically significant association was obtained.

**Supplementary Table S3.** Comparative analysis of RSPO3 and clinically relevant biomarkers (ER, PR, and Her2) expression levels by IHC using a breast cancer tissue micro-array

<b>Biomarker profile</b>	<b>RSPO3</b>							
	<b>Negative</b>		<b>Low</b>		<b>Strong</b>		<b>Total</b>	
	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>
<b>PR (-) ER (-) Her2 (-)</b>	4	40.0	4	40.0	2	20.0	<b>10</b>	<b>100</b>
<b>PR (+) ER (+) Her2 (+)</b>	4	21.1	7	36.8	8	42.1	<b>19</b>	<b>100</b>
<b>PR (-) ER (-) Her2 (+)</b>	8	30.8	11	42.3	7	26.9	<b>26</b>	<b>100</b>
<b>PR (+) ER (+) Her2 (-)</b>	4	40.0	5	50.0	1	10.0	<b>10</b>	<b>100</b>
<b>PR (-) ER (+) Her2 (-)</b>	1	33.3	2	66.7	0	0.0	<b>3</b>	<b>100</b>
<b>PR (+) ER (-) Her2 (+)</b>	0	0.0	0	0.0	1	100.0	<b>1</b>	<b>100</b>
<b>PR (-) ER (+) Her2 (+)</b>	1	20.0	2	40.0	2	40.0	<b>5</b>	<b>100</b>
<b>PR (+) ER (+) Her2 (-)</b>	0	0.0	0	0.0	0	0.0	<b>0</b>	<b>0</b>
<b>Total</b>	<b>22</b>	<b>29.7</b>	<b>31</b>	<b>41.9</b>	<b>21</b>	<b>28.4</b>	<b>74</b>	<b>100</b>

**Supplementary Table S4.** Comparative analysis of RSPO3 and Ki67 expression by IHC using a breast cancer tissue micro-array

Ki67	RSPO3					
	Negative		Positive		Total	
	n	%	n	%	n	%
<b>Negative</b>	6	33.3	12	66.6	<b>18</b>	<b>100</b>
<b>Positive</b>	16	28.6	40	71.4	<b>56</b>	<b>100</b>
<b>Total</b>	<b>22</b>	<b>29.7</b>	<b>52</b>	<b>70.3</b>	<b>74</b>	<b>100</b>

Non-statistically significant association was obtained; Chi-squared test; p=0.770.